Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Anton Pozniak, Martin Markowitz, Anthony Mills, Hans Juergen Stellbrink, Antonio Antela, Pere Domingo, Pierre Marie Girard, Keith Henry, Thai Nguyen, David Piontkowsky, Will Garner, Kirsten White, Bill Guyer

Research output: Contribution to journalArticlepeer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial'. Together they form a unique fingerprint.

Medicine & Life Sciences